Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 1/2013

01-02-2013 | Original Article

Locoregional recurrence risk factors in breast cancer patients with positive axillary lymph nodes and the impact of postmastectomy radiotherapy

Authors: Tomoya Nagao, Takayuki Kinoshita, Nobuko Tamura, Takashi Hojo, Madoka Morota, Yoshikazu Kagami

Published in: International Journal of Clinical Oncology | Issue 1/2013

Login to get access

Abstract

Background

Locoregional recurrence (LRR) after mastectomy reduces the patient’s quality of life and survival. There is a consensus that postmastectomy radiotherapy (PMRT) helps establish locoregional control and reduces LRR in patients with ≥4 metastatic nodes. However, in patients with 1–3 metastatic nodes, the incidence of LRR and the role of PMRT have been the subject of substantial controversy. This study assessed the risk factors for LRR and the efficacy of PMRT in Japanese breast cancer patients with metastatic nodes.

Methods

This study analyzed 789 cases of invasive breast carcinoma with metastatic nodes from 1998 to 2008. We divided the study population into 4 groups: 1–3 positive nodes with/without chemotherapy and ≥4 positive nodes with/without chemotherapy. Risk factors for LRR were identified and the relationship between LRR and PMRT was analyzed.

Results

During the median follow-up of 59.6 months, 61 (7.7%) patients experienced LRR. In patients who received chemotherapy, independent LRR risk factors were high nuclear grade, severe lymphatic invasion, vascular invasion, and progesterone receptor-negative status in patients with 1–3 positive nodes, and severe lymphatic invasion and estrogen receptor-negative status in patients with ≥4 nodes. Although patients treated with PMRT had good outcomes, there was no significant difference, and PMRT did not significantly improve the outcome of the patients with all risk factors.

Conclusions

With systemic therapy and adequate dissection, PMRT by itself was of limited value in establishing locoregional control. The indication for PMRT in patients with 1–3 positive nodes remains controversial.
Literature
1.
Overgaad M, Hansen PS, Overgaard J et al (1997) Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. N Engl J Med 337:949–955CrossRef
2.
Ragaz J, Jackson SM, Le N et al (1997) Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 337:956–962PubMedCrossRef
3.
Olson JE, Neuberg D, Pandya KJ et al (1997) The role of radiotherapy in the management of operative locally advanced breast cancer: results of a randomized trial by the Eastern Cooperative Oncology Group. Cancer 79:1138–1149PubMedCrossRef
4.
Pierce LJ (2006) The use of radiotherapy after mastectomy: a review of the literature. J Clin Oncol 23:1706–1717CrossRef
5.
Katz A, Strom EA, Buchholz TA et al (2001) The influence of pathologic tumor characteristics on locoregional recurrence rates following mastectomy. Int J Radiat Oncol Biol Phys 50:733–742
6.
Overgaard M, Nielsen HM, Overgaard J (2007) Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiother Oncol 82:247–253PubMedCrossRef
7.
Truong PT, Olivotto IA, Whelan TJ et al (2004) Clinical practice guidelines for the care and treatment of breast cancer: 16. Locoregional post-mastectomy radiotherapy. CMAJ 170:1263–1273PubMedCrossRef
8.
Marks LB, Zeng J, Prosnitz LR (2008) One to three versus four or more positive nodes and postmastectomy radiotherapy: time to end the debate. J Clin Oncol 28:2075–2077CrossRef
9.
Goldhirsch A, Glick JH, Gelber RD et al (1998) Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 90:1601–1608PubMedCrossRef
10.
Goldhirsch A, Glick JH, Gelber RD et al (2001) Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Clin Oncol 19:3817–3827PubMed
11.
Goldhirsch A, Wood WC, Gelber RD et al (2003) Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 21:3357–3365
12.
Goldhirsch A, Glick JH, Gelber RD et al (2005) Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16:1569–1583PubMedCrossRef
13.
Goldhirsch A, Wood WC, Gelber RD et al (2007) Progress and promise: highlights of international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18:1133–1144PubMedCrossRef
14.
The World Health Organization (1983) The World Health Organization histological typing of breast tumors second edition. Am J Clin Pathol 78:806–816
15.
Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histopathological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403–410PubMedCrossRef
16.
The Japanese Breast Cancer Society (2008) General rules for clinical and pathological recording of breast cancer, 16th edn. Kanehara, Tokyo (in Japanese)
17.
Tsuda H, Akiyama F, Kurosumi M et al (1998) Establishment of histological criteria for high-risk node-negative breast carcinoma for a multi-institutional randomized clinical trial of adjuvant therapy. Jpn J Clin Oncol 28:486–491PubMedCrossRef
18.
Katz A, Strom EA, Buchholz TA et al (2000) Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implication for postoperative irradiation. J Clin Oncol 18:2817–2827PubMed
19.
Wallgren A, Bonetti RD, Gelber RD et al (2003) Risk factors for locoregional recurrence among breast cancer patients: results from international breast cancer study group trials I through VII. J Clin Oncol 21:1205–1213PubMedCrossRef
20.
Nielsen HM, Overgaard M, Grau C et al (2006) Loco-regional recurrence after mastectomy in high-risk breast cancer-risk and prognosis. An analysis of patients from the DBCG 82 b&c randomization trials. Radiother Oncol 79:147–155PubMedCrossRef
21.
Yildirum E (2009) Locoregional recurrence in breast carcinoma patients. Eur J Surg Oncol 35:258–265CrossRef
22.
Taghian A, Jeong JH, Mamounas E et al (2004) Patterns of locoregional failure in patients with operative breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized clinical trials. J Clin Oncol 22:4247–4254PubMedCrossRef
23.
Kyndi M, Sørensen FB, Knudsen H et al (2009) Response to postmastectomy radiotherapy in high-risk breast cancer: the Danish breast cancer cooperate group. J Clin Oncol 26:1419–1426CrossRef
Metadata
Title
Locoregional recurrence risk factors in breast cancer patients with positive axillary lymph nodes and the impact of postmastectomy radiotherapy
Authors
Tomoya Nagao
Takayuki Kinoshita
Nobuko Tamura
Takashi Hojo
Madoka Morota
Yoshikazu Kagami
Publication date
01-02-2013
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 1/2013
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-011-0343-y

Other articles of this Issue 1/2013

International Journal of Clinical Oncology 1/2013 Go to the issue

Original Article

Computed tomography fluoroscopy-guided radiofrequency ablation following intra-arterial iodized-oil injection for hepatocellular carcinomas invisible on ultrasonographic images

Original Article

Salvage chemotherapy for recurrent or persistent clear cell carcinoma of the ovary: a single-institution experience for a series of 20 patients

Original Article

Enhanced antitumor effect of lower-dose and longer-term CPT-11 treatment in combination with low-dose celecoxib against neuroblastoma xenografts

Original Article

Neoadjuvant and adjuvant chemotherapy with modified mesna, adriamycin, ifosfamide, and dacarbazine (MAID) regimen for adult high-grade non-small round cell soft tissue sarcomas

Original Article

The prognostic analysis of clinical breast cancer subtypes among patients with liver metastases from breast cancer

Original Article

Comparison of safety and efficacy of S-1 monotherapy and S-1 plus cisplatin therapy in elderly patients with advanced gastric cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits